The prognostic value of the serum level of Creactive protein for the survival of patients with a primary sarcoma of bone

Journal of Bone and Joint Surgery - Series B

Volumn 95 B, Issue 3, 2013, Pages 411-418

  Nakamura, T ^a   Grimer, R J ^a   Gaston, C L ^a   Watanuki, M ^a,b   Sudo, A ^a,c   Jeys, L ^a  

^a ROYAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE GRAFT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CHILD; CHONDROSARCOMA; DISEASE SPECIFIC SURVIVAL; EWING SARCOMA; FEMALE; HUMAN; HUMAN TISSUE; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; OVERALL SURVIVAL; PREOPERATIVE PERIOD; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT RESPONSE; TUMOR VOLUME; CANCER CONTROL; CANCER SURVIVAL; DIAGNOSTIC TEST ACCURACY STUDY; HIGH RISK PATIENT; PREDICTIVE VALUE; SURVIVAL PREDICTION; SURVIVAL RATE; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; C-REACTIVE PROTEIN; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; SARCOMA; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84874728162     PISSN: 0301620X     EISSN: None     Source Type: Journal    
DOI: 10.1302/0301-620X.95B3     Document Type: Article

References (27)

1. Grimer R, Athanasou N, Gerrand C, et al. UK guidelines for the management of bone sarcomas. Sarcoma 2010;2010:317462.
2. Leavey PJ, Collier AB. Ewing sarcoma: Prognostic criteria, outcomes and future treatment. Expert Rev Anticancer Ther 2008;8:617-624.
3. Aljubran AH, Griffin A, Pintille M, Blackstein M. Osteosarcoma in adolescents and adults: Survival analysis with and without lung metastases. Ann Oncol 2009;20:1136-1140.
4. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1702 patients treated on neoadyuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20:776-790.
5. Bacci G, Ferrari S, Bertoni F, et al. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy analysis of 359 patients at the Instituto Orthopedico Rizzoli. J Clin Oncol 2000;18:4-10.
6. Giuffrida AY, Burgueno JE, Koniaris LG, et al. Chondrosarcoma in the United States (1973 to 2003): An analysis of 2890 cases from the SEER database. J Bone Joint Surg [Am] 2009;91-A:1063-1072.
7. Karakiewicz PI, Hutterer GC, Trinh QD, et al. C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: A European study of 313 patients. Cancer 2007;110:1241-1247.
8. Kim DK, Oh SY, Kwon HC, et al. Clinical significance of preoperative serum interleulin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer 2009;9:155.
9. Pierce BL, Ballard-Barbash R, Bernstein L, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 2009;27:3437-3444.
10. McMillian DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 2003;90:215-219.
11. Scott HR, McMillan DC, Forrest LM, et al. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer 2002;87:264-267.
12. Stark JR, Li H, Kraft P, et al. Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality. Int J Cancer 2009;124:2683-2689.
13. Falconer JS, Fearson KC, Ross JA, et al. Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer 1995;75:2077-2082.
14. Nazoe T, Saeki H, Sugimachi K. Significance of preoperative elevation of serum Creactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg 2001;182:197-200.
15. Nakanishi H, Araki N, Kudawara I, et al. Clinical implications of serum C-reactive protein levels in malignant fibrous histiocytoma. Int J Cancer 2002;99:167-170.
16. Nakamura T, Matsumine A, Matsubara T, et al. Clinical significance of pretreatment serum C-reactive protein level in soft tissue sarcoma. Cancer 2012;118:1055-1060.
17. Funovics PT, Edelhauser G, Funovics MA, et al. Pre-orerative serum C-reactive protein as independent prognostic factor for survival but not infection in patients with high-grade osteosarcoma. Int Orthop 2011;35:1529-1536.
18. Athanasou N, Bielack S, Alava ED, et al. Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow up. Ann Oncol 2010;21(Suppl 5):204-213.
19. Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in chondrosarcoma of bone: A clinicopathologic analysis with emphasis on histologic grading. Cancer 1977;40:818-830.
20. Edge SB, Byrd DR, Compton CC, et al. Bone sarcoma. In: AJCC cancer staging manual. 7th ed. New York: Springer, 2010:281-290.
21. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-867.
22. Mantovani G, Macciò A, Pisano M, et al. Tumor-associated lympho-monocytes from neoplastic effusions are immunologically defective in comparison with patients autologous PBMCs are capable of releasing high amounts of various cytokines. Int J Cancer 1997;71:724-730.
23. Ramsey S, Lamb GW, Aitchison M, McMillan DC. The longitudinal relationship between circulating concentrations of C-reactive protein, interleukin-6 and interleukin-10 in patients undergoing resection for renal cancer. Br J Cancer 2006;95:1076-1080.
24. Castell JV, Gómez-Lechón MJ, David M, et al. Acute-phase response of human hepatocytes; regulation of acute-phase protein synthesis by interleukin-6. :Hepatology 1990;12:1179-1186.
25. Nazoe T, Korenaga D, Futatsugi M, et al. Immunohistochemical expression of Creactive protein in squamous cell carcinoma of the esophagus: Significance as a tumor marker. Cancer Lett 2003;192:89-95.
26. Wigmore SJ, Fearon KC, Sangster K, et al. Cytokine regulation of constitutive production of interleukin-8 and-6 by human pancreatic cancer cell lines and serum cytokine concentrations in patients with pancreatic cancer. Int J Oncol 2002;21:881-886.
27. Rutkowski P, Kaminska J, Kowalska M, Ruka W, Steffen J. Cytokine serum levels in adult bone sarcoma patients: Correlations with local tumor extent and prognosis. J Surg Oncol 2003;84:151-159.